[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362405-105":59,"doc-detail-362405-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","bibliometric-analysis-of-research-trends-and-hotspots-in-immunotherapy-biomarkers-for-non-small-cell-lung-cancer-from-2015-to-2024","Bibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024","","Bibliometric analysis evaluates research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer (NSCLC) between 2015 and 2024. Web of Science Core Collection articles and reviews (retrieved June 23, 2025) were analyzed with CiteSpace and VOSviewer, including network mapping of countries, institutions, authors, journals, co-cited references, and keywords. The study includes 2,134 publications from 14,723 researchers across 73 countries and 3,670 institutions in 427 journals, highlighting key emerging topics including ICIs, PD-L1, TMB, liquid biopsy, tumor microenvironment, radiomics, and gut microbiota.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bibliometric-analysis-of-research-trends-and-hotspots-in-immunotherapy-biomarkers-for-non-small-cell-lung-cancer-from-2015-to-2024/362405/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bibliometric-analysis-of-research-trends-and-hotspots-in-immunotherapy-biomarkers-for-non-small-cell-lung-cancer-from-2015-to-2024/362405.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this bibliometric analysis?","Question",{"text":113,"@type":114},"To identify research hotspots and emerging themes in immunotherapy biomarkers for NSCLC from 2015 to 2024.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the publications retrieved and analyzed?",{"text":118,"@type":114},"Articles and reviews from the Web of Science Core Collection were retrieved for January 1, 2015–December 31, 2024, then analyzed using CiteSpace and VOSviewer with network visualizations.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immunotherapy biomarker topics were highlighted as key areas?",{"text":122,"@type":114},"Key topics included immune checkpoint inhibitors (ICIs), PD-L1, tumor mutational burden (TMB), liquid biopsy, and combination therapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},362405,1790183301,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Meng et al. Discover Oncology (2026) 17:295 [https://doi.org/10.1007/s12672-026-04436-z](https://doi.org/10.1007/s12672-026-04436-z)  \nDiscover Oncology  \nRESEARCH Open Access  \nBibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024  \nXiangnv Meng1*†, Zhongting Lu2† and Fu Mi 1  \n†Xiangnv Meng and Zhongting Lu contributed equally to this work.  \n*Correspondence: Xiangnv Meng  \nmengxiangnv1 [123@163.com](123@163.com)  \n1Second Department of Medical Oncology, Cangzhou Central Hospital, Cangzhou, Hebei, China 2General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China  \nAbstract  \nBackground Immunotherapy has revolutionized the treatment of non-small cell lung cancer (NSCLC), offering promising alternatives to traditional therapies. This study aimed to conduct a bibliometric analysis to identify research hotspots and emerging themes in immunotherapy biomarkers for NSCLC from 2015 to 2024.  \nMethods Articles and reviews from the Web of Science Core Collection (January 1, 2015–December 31, 2024) were retrieved on June 23, 2025. Networks of countries, institutions, authors, journals, co-cited references, and keywords were constructed using CiteSpace and VOSviewer, with visualizations created using Scimago Graphica. Results A total of 2134 publications by 14,723 researchers from 73 countries and 3670 institutions, across 427 journals, were included. The number of annual publications increased steadily, peaking at 404 in 2024. China led in publication volume, while the U. S. had the highest citation impact. Tongji University was the most productive institution, and Caicun Zhou was the most prolific author. Among the journals, Cancers had the highest publication volume, while Lung Cancer had the highest citation frequency. The key topics identified included immune checkpoint inhibitors (ICIs), programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), liquid biopsy, and combination therapy. Emerging fields included the tumor microenvironment (TME), radiomics, proliferative signaling, and the gut microbiota.  \nConclusion This bibliometric analysis provides a comprehensive overview of NSCLC immunotherapy biomarker research, highlighting key trends and emerging directions. These insights are crucial for advancing precision immunotherapies and biomarkerdriven strategies.  \nKeywords NSCLC, Immunotherapy, Biomarkers, Bibliometric analysis, Data visualization  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nMeng et al. Discover Oncology (2026) 17:295 Page 2 of 25  \nGraphical Abstract  \n1 Introduction  \nNon-small cell lung cancer (NSCLC) remains the leading cause of cancer-related morbidity and mortality worldwide, accounting for approximately 85% of all lung cancer cases [1–3]. Although conventional treatment modalities—including surgery, chemotherapy, and radiotherapy—provide clinical benefit for selected patients, their impact on ove","cbCaiaM5691Hgggq","https://ap.wps.com/l/cbCaiaM5691Hgggq","pdf",6020841,25,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main purpose of this bibliometric analysis?\",\"answer\":\"To identify research hotspots and emerging themes in immunotherapy biomarkers for NSCLC from 2015 to 2024.\"},{\"question\":\"How were the publications retrieved and analyzed?\",\"answer\":\"Articles and reviews from the Web of Science Core Collection were retrieved for January 1, 2015–December 31, 2024, then analyzed using CiteSpace and VOSviewer with network visualizations.\"},{\"question\":\"Which immunotherapy biomarker topics were highlighted as key areas?\",\"answer\":\"Key topics included immune checkpoint inhibitors (ICIs), PD-L1, tumor mutational burden (TMB), liquid biopsy, and combination therapy.\"}]","Bibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024 | PDF",1790147563,63,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b40b1e2e14435d43c71cfea374802c11.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52f3da9cda90079eb111be005d5cd732.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abb36b94e93e0403756316ab5ba32c92.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85900ffd2771381f5091ad8e5853c139.webp",980,1306]